Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disorders immunotherapeutics and diagnostics - ProMIS Neurosciences

Alternative Names: Amorfix EP-AD; Disease specific epitope (DSE) monoclonal antibodies; Neurodegenerative disorders monoclonal antibodies - Amorfix Life Sciences; Neurodegenerative disorders vaccines - Amorfix Life Sciences

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; University of British Columbia
  • Class Diagnostic agents; Vaccines
  • Mechanism of Action Immunomodulators; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Preclinical Alzheimer's disease
  • Research Amyotrophic lateral sclerosis
  • Suspended Creutzfeldt-Jakob disease

Most Recent Events

  • 28 Mar 2017 Preclinical development in Amyotrophic lateral sclerosis and Alzheimer's disease is ongoing in Canada
  • 08 Oct 2015 ProMIS Neurosciences expands exclusive license agreement with the University of British Columbia to gain worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications and enhancements to ProMIS™ technology
  • 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top